Stage IV Melanoma Completed Phase 3 Trials for Sargramostim (DB00020)

IndicationStatusPhase
DBCOND0028660 (Stage IV Melanoma)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01989572Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By SurgeryPrevention